BLASUBCUTANEOUSINJECTABLE
Approved
Dec 2025
Lifecycle
Launch
Competitive Pressure
30/100
Data completeness
2/8 — Basic
OZILTUS (denosumab-mobz) by Amneal Pharms is rank ligand blocking activity [moa]. First approved in 2025.
Drug data last refreshed 2h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OZILTUS (denosumab-mobz) is a monoclonal antibody that blocks RANK ligand, inhibiting osteoclast activation and bone resorption. This is a biosimilar to the reference denosumab product, indicated for bone loss conditions where osteoclast suppression is therapeutically beneficial. The mechanism targets a key pathway in bone homeostasis, making it applicable across multiple indications involving pathological bone loss.
Launch
Early-stage biosimilar launch with moderate competitive pressure (30) suggests growth phase opportunities in market access, contracting, and field teams as market penetration ramps.
Mechanism of Action
RANK Ligand Blocking Activity
Pharmacologic Class:
RANK Ligand Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Joining the OZILTUS team offers exposure to biosimilar commercialization, payer negotiation, and market penetration strategies in a newly launched product. Career growth will be driven by contracting wins, market share gains, and organizational scaling during early lifecycle phases.
Brand ManagerMarket Access Manager
Worked on OZILTUS at Amneal Pharms? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.